Anesthetics and Analgesics in Children

Description

The purpose of this study is to characterize the pharmacokinetic (PK) and safety profile of anesthetics and analgesics in children and adolescents.

Conditions

Anesthesia, Pain

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to characterize the pharmacokinetic (PK) and safety profile of anesthetics and analgesics in children and adolescents.

Pharmacokinetics of Anesthetics and Analgesics in Children and Adolescent

Anesthetics and Analgesics in Children

Condition
Anesthesia
Intervention / Treatment

-

Contacts and Locations

Stanford

Lucile Packard Children's Hospital, Stanford, California, United States, 94305

Aurora

Children's Hospital Colorado, Aurora, Colorado, United States, 80045

Wilmington

Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States, 19803

Chicago

Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States, 60611

Saint Louis

Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States, 63104

Saint Louis

Washington University School of Medicine, Saint Louis, Missouri, United States, 63110

Durham

Duke University Medical Center, Durham, North Carolina, United States, 27701

Portland

Oregon Health and Science University, Portland, Oregon, United States, 97239

Charleston

Medical University of South Carolina, Charleston, South Carolina, United States, 29425

Austin

Dell Children's Medical Center of Texas, Austin, Texas, United States, 78723

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. 0 to \<18 years of age at time of enrollment (must see applicable appendix for details as not all appendices enroll across the entire age range)
  • 2. Parent and/or participant (if applicable) is able to understand the consent process and provides informed consent and HIPAA Authorization (if applicable)
  • 3. Participant provides assent as required by the institutional review board (IRB) or research ethics board (REB)
  • 4. Receiving one or more drugs of interest (DOI) per local standard of care
  • 5. Meeting DOI-specific inclusion criteria (See Appendices)
  • 1. Known pregnancy
  • 2. Extracorporeal life support (i.e., ECMO, dialysis, ventricular assist device)
  • 3. Any condition which would make the participant, in the opinion of the investigator, unsuitable for the study

Ages Eligible for Study

0 Years to 17 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Kanecia Obie Zimmerman,

Kanecia Zimmerman, PRINCIPAL_INVESTIGATOR, Duke Clinical Research Institute

Study Record Dates

2025-06-30